Cosmo Pharmaceuticals announces FDA Approval for Cassiopea’s Winlevi® (clascoterone cream 1%), First-in-Class Topical Acne Treatment Targeting the Androgen Receptor
The approval of WINLEVI brings the first truly new mechanism of action in acne treatment in nearly 40 years
Cosmo Pharmaceuticals NV announced today that Cassiopea SpA, a company in which it holds 46.56% of the shares, today announced that the United States Food and Drug Administration (FDA) approved Winlevi® (clascoterone cream 1%) for the treatment of acne in patients 12 years and older.